6CM
AQST icon

683 Capital Management’s Aquestive Therapeutics AQST Stock Holding History

683 Capital Management’s Portfolio AQST Stock Details AQST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-93,510
Closed -$189K – 150
2023
Q4 		$189K Buy
+93,510
New +$165K 0.02% 208
2020
Q1 		– Sell
-33,422
Closed -$195K – 151
2019
Q4 		$195K Buy
+33,422
New +$174K 0.02% 107

Other funds holding AQST

BCM
Bratton Capital Management Fort Worth, Texas $40.7M AUM 43.1% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MIM
Monashee Investment Management Boston, Massachusetts $184M AUM 197.43% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return

683 Capital Management's AQST Position: Q1 2024 in Review

683 Capital Management sold out of Aquestive Therapeutics (AQST) in Q1 2024, closing a stake of 93,510 shares — an estimated $189K sold.

683 Capital Management first reported a position in AQST in Q4 2019 and held it in 2 quarters. The position peaked at $195K in Q4 2019. 97 funds tracked by Wall St. Rank hold AQST as of Q1 2024.

  • 683 Capital Management reported no remaining Aquestive Therapeutics position as of Q1 2024 after selling out during the quarter.
  • 683 Capital Management sold 93,510 Aquestive Therapeutics shares in Q1 2024, an estimated $189K.
  • 683 Capital Management first reported a position in Aquestive Therapeutics in Q4 2019 and held it in 2 quarters.
  • 683 Capital Management's Aquestive Therapeutics position peaked at $195K in Q4 2019.
  • 97 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q1 2024.

Based on 683 Capital Management's 13F filing for Q1 2024, filed 15 May 2024.